Core Insights - Halozyme Therapeutics is experiencing significant growth driven by the adoption of subcutaneous (subcu) therapies, particularly with argenx's VYVGART Hytrulo and the success of DARZALEX subcu, which has reached a 96% adoption rate among U.S. patients [2][3] Group 1: Business Overview - The recent acquisition of Elektorfi for its Hypercon technology aims to enhance patient access to biologic therapies through simple auto-injectors, indicating a strategic move to expand home treatment options [3] - Halozyme's portfolio now includes three leading technologies: ENHANZE, which is approved for 10 products and contributes to strong royalty revenue growth, and the high-volume auto-injector, which complements the existing offerings [4]